Coherus Content With Dual Pipeline Strategy

US Firm Reveals Full-Year Udenyca Biosimilar Sales

03 Mar 2020

Coherus BioSciences sees value in having both wholly-owned and in-licensed biosimilar assets, as the firm gears up to have a portfolio of at least six products within five years.

Road_Mountain — Coherus is finally in year-end profit after launching its first product • Source: Shutterstock

Coherus BioSciences aims to continue balancing internally-developed biosimilars with in-licensed product opportunities, as the US-based player enters its 2020 financial year cash flow positive from operations following a virtual full year of wholly-owned Udenyca (pegfilgrastim-cbqv) sales.

Denny Lanfear, Coherus’ president, CEO and chairman, told investors at the company’s year-end financial results call, “I think that it's...